Life sciences distribution is shifting toward AI-powered, resilient networks that improve speed, efficiency, compliance, and ...

On this weeks episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets ...

After 30 years of use in transplant medicine, EBV-specific T cells offer key lessons for safer, scalable allogeneic cell therapies, writes Ivan Horak, M.D.

On this weeks episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to ...

Candidates for seats on company boards should scrutinize governance, culture, and leadership dynamics before saying yes, ...

Few scientific careers follow a single straight line. Stacy Blain, Ph.D., followed a single protein. As a molecular and cell biologist, Blain has spent more than 30 years studying p27, a regulatory ...

On this week's episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why ...

My father was a lawyer in New York City. He built his own practice from nothing, the way immigrants do. Through discipline, reputation, a little grit, and an almost stubborn insistence on doing right ...

A company launching a drug in the United States in 2027 will hire its contract sales organization (CSO) from a market that has changed since its executives last bought from it. Five of the best-known ...

On this week's episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s. He describes Moonwalk’s ...

On this week's episode of the Business of Biotech, Independent Board Director and five-time public company CFO Alan Shaw returns to the show for an update on current biotech financing and the ...